Private company

Viracta Therapeutics, Inc.

American pharmaceutical preparations company based in South San Francisco2

In its 2024 annual report the company says: “Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide.”4

Last updated Oct 20, 2026.

Overview

  • IndustryPharmaceutical Preparations2
  • HeadquartersSouth San Francisco, United States2
  • Incorporated inDE3
  • Business address2533 S Coast Hwy 101, Suite 210, Cardiff, Ca 920073
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI549300O5S543GE2D9G672
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O THE CORPORATION TRUST COMPANY, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 28570222

See how the biggest companies compare on our leaderboards

Viracta Therapeutics, Inc. (“Viracta” or the “Company”) is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide. The association of viruses and cancer has been well characterized, and Viracta’s lead program is focused on cancers associated with the Epstein-Barr virus (“EBV”). EBV has been recognized as a Group 1 human carcinogen by the World Health Organization (“WHO”). Despite the association of EBV with cancer, there are currently no approved therapies in the United States specifically for EBV-associated cancers and attempts to develop vaccines have not proven successful. EBV enters periods of latency during which most viral genes are epigenetically suppressed. Likewise, the latently infected cell can evade the body’s immune surveillance mechanisms. In some stages of latency, viral proteins are no…4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2020

-15679.2%Operating margin5
-15847.5%Net margin5
-94.2%Revenue growth, 20206
-$16.1MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2020

  • Research and development98¢$12.3M
  • Interest2¢$216.0K

Out of $120.0K in revenue.65 The company lost money this year.

Financial statements

Revenue786$120.0K in 2020−82% since 2017
0$1.0M$2.0M$3.0M2017: $669.0K$669.0K20172018: $237.0K$237.0K2018−65%2019: $2.1M$2.1M2019+775%2020: $120.0K$120.0K2020−94%
Operating income7865-$18.8M in 2020−45% since 2017
-$40.0M-$30.0M-$20.0M-$10.0M02017: -$34.4M-$34.4M20172018: -$25.7M-$25.7M2018−25%2019: -$23.3M-$23.3M2019−9%2020: -$18.8M-$18.8M2020−19%
Net income7865-$19.0M in 2020−46% since 2017
-$40.0M-$30.0M-$20.0M-$10.0M02017: -$35.5M-$35.5M20172018: -$26.6M-$26.6M2018−25%2019: -$23.3M-$23.3M2019−12%2020: -$19.0M-$19.0M2020−18%
Fiscal year2017201820192020
Revenue$669.0K7$237.0K8$2.1M6$120.0K6
Research and development$21.5M7$14.6M8$15.4M6$12.3M6
Operating expenses
Operating income-$34.4M7-$25.7M8-$23.3M6-$18.8M5
Interest$1.4M7$1.2M8$514.0K6$216.0K5
Income tax$07$08$06$05
Net income-$35.5M7-$26.6M8-$23.3M6-$19.0M5
Earnings per share-$1.4511
Earnings per share (diluted)-$1.4511
Shares (weighted, basic)
Shares (weighted, diluted)

Compare Viracta Therapeutics, Inc. with another company

Corporate structure

Viracta Therapeutics, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Viracta Therapeutics, Inc.

  • FORWARD VENTURES V LP Filed SCHEDULE 13G on Viracta Therapeutics, Inc., latest Feb 14, 2025 (3 filings since Feb 9, 2022)
  • BIOTECHNOLOGY VALUE FUND L P Filed SC 13G/A on Viracta Therapeutics, Inc., latest Nov 14, 2024 (3 filings since Feb 14, 2022)
  • Yair Chaim Schindel Filed SC 13D/A on Viracta Therapeutics, Inc., latest Jan 10, 2023
  • Laurence W. Lytton Filed SC 13G/A on Viracta Therapeutics, Inc., latest Feb 15, 2022
  • Aisling Capital IV, LP Filed SC 13G on Viracta Therapeutics, Inc., latest Feb 14, 2022
  • Viracta Therapeutics, Inc. South San Francisco, California, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Viracta Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$190.0K13 Dec 31, 2023$148.0K13 Dec 31, 2022+28.4%
Operating-lease assets (leased space)$274.0K13 Dec 31, 2023$266.0K13 Dec 31, 2022+3.0%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$12.3M13 Dec 31, 2023$36.8M13 Dec 31, 2022−66.5%
Marketable securities, current$41.4M13 Dec 31, 2023$54.3M13 Dec 31, 2022−23.8%

Leadership

Who has led Viracta Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Daniel N. Swisher Jr.2006–2017
  2. Dayton Misfeldt2018–2020
  3. Daniel R. Chevallard2021
  4. Ivor Royston2021–2022
  5. Mark Rothera2022–2024

Chair

  1. James W. Young2006–2007

President

  1. Daniel N. Swisher Jr.2006–2017
  2. Ivor Royston2021–2022
  3. Mark Rothera2022–2024

Chief financial officer

  1. Eric Bjerkholt2006–2016
  2. William P. Quinn2017–2019
  3. Daniel R. Chevallard2021–2024
  4. Michael E. Faerm2024

Chief operating officer

  1. Daniel R. Chevallard2021–2024
2010201520202025
Board members and other officers (46)

Former names

  • SUNESIS PHARMACEUTICALS INCAug 7, 2002 to Mar 2, 20213

Timeline

  1. Feb 5, 20258-K Exit or restructuring costs; Executive or director change; Other events67
  2. Jan 31, 20258-K Listing notice or transfer68
  3. Jan 24, 20258-K Entered a material agreement; Debt or obligation accelerated69
  4. Jan 17, 20258-K Listing notice or transfer70
  5. Dec 26, 20248-K Executive or director change71
  6. Nov 29, 20248-K Listing notice or transfer72
  7. Nov 22, 20248-K Listing notice or transfer73
  8. Nov 13, 20248-K Results of operations74
  9. Nov 6, 20248-K Exit or restructuring costs; Executive or director change; Regulation FD disclosure75
  10. Aug 14, 20248-K Results of operations; Regulation FD disclosure76
  11. Jul 29, 20248-K Exit or restructuring costs77
  12. Jun 20, 20248-K Shareholder vote78
  13. Sep 19, 2022New chief executive Mark Rothera becomes CEO14
  14. Feb 24, 2021New chief executive Ivor Royston becomes CEO16
  15. Feb 24, 2021New chief executive Daniel R. Chevallard becomes CEO15
  16. Jan 2, 2018New chief executive Dayton Misfeldt becomes CEO17
  17. Oct 17, 2006New chief executive Daniel N. Swisher Jr. becomes CEO18
  18. Feb 10, 1998Founded Viracta Therapeutics, Inc. is founded2

Calendar

When it reported results

  1. Nov 13, 2024Reported quarterly or annual results74
  2. Aug 14, 2024Reported quarterly or annual results76
  3. May 9, 2024Reported quarterly or annual results79
  4. Mar 7, 2024Reported quarterly or annual results80
  5. Nov 9, 2023Reported quarterly or annual results81
  6. Aug 14, 2023Reported quarterly or annual results82
  7. May 8, 2023Reported quarterly or annual results83
  8. Mar 13, 2023Reported quarterly or annual results84

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

176 filings to the SEC since October 2021: 3 annual reports, 10 quarterly reports, 42 major events, 92 insider forms, 11 large holders, 18 other. The latest 20:

  1. Jul 10, 202525-NSE EDGAR
  2. Feb 14, 2025SCHEDULE 13G EDGAR
  3. Feb 5, 20258-K EDGAR
  4. Jan 31, 20258-K EDGAR
  5. Jan 24, 20258-K EDGAR
  6. Jan 17, 20258-K EDGAR
  7. Dec 26, 20248-K EDGAR
  8. Nov 29, 20248-K EDGAR
  9. Nov 27, 20244 EDGAR
  10. Nov 27, 20244 EDGAR
  11. Nov 22, 20248-K EDGAR
  12. Nov 14, 2024SC 13G/A AMENDMENT NO. 10 TO SCHEDULE 13G EDGAR
  13. Nov 13, 202410-Q EDGAR
  14. Nov 13, 20248-K EDGAR
  15. Nov 6, 20248-K EDGAR
  16. Sep 12, 20244 EDGAR
  17. Sep 12, 20244 EDGAR
  18. Aug 14, 202410-Q EDGAR
  19. Aug 14, 20248-K EDGAR
  20. Jul 29, 20248-K EDGAR

The 176 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

26 open-market trades by officers, directors and large owners since October 2021: 3 buys and 23 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Feb 27, 2024Chevallard Daniel R.CFO and COOSale3,405$0.73$2.5KForm 4
Dec 1, 2023Rothera MarkPresident and CEOBuy47,906$0.49$23.5KForm 4
Nov 30, 2023Rothera MarkPresident and CEOBuy52,094$0.49$25.5KForm 4
Nov 28, 2023Chevallard Daniel R.CFO and COOSale3,720$0.50$1.9KForm 4
Aug 28, 2023Chevallard Daniel R.CFO and COOSale3,512$1.45$5.1KForm 4
May 25, 2023Chevallard Daniel R.CFO and COOSale3,635$1.42$5.2KForm 4
Feb 27, 2023Rojkjaer LisaChief Medical OfficerSale2,156$1.68$3.6KForm 4
Feb 27, 2023Chevallard Daniel R.CFO and COOSale3,599$1.68$6.0KForm 4
Nov 28, 2022Chevallard Daniel R.CFO and COOSale3,532$2.72$9.6KForm 4
Nov 28, 2022Rojkjaer LisaChief Medical OfficerSale2,116$2.72$5.8KForm 4
Aug 26, 2022Rojkjaer LisaChief Medical OfficerSale2,190$4.01$8.8KForm 4
Aug 26, 2022Chevallard Daniel R.CFO and COOSale3,655$4.02$14.7KForm 4
Aug 26, 2022ROYSTON IVORDirectorSale13,379$4.01$53.6KForm 4
May 26, 2022ROYSTON IVORDirectorSale13,162$1.90$25.0KForm 4
May 26, 2022Rojkjaer LisaChief Medical OfficerSale2,154$1.90$4.1KForm 4
May 26, 2022Chevallard Daniel R.CFO and COOSale3,596$1.90$6.8KForm 4
Feb 28, 2022ROYSTON IVORDirectorSale14,635$2.78$40.7KForm 4
Feb 28, 2022Rojkjaer LisaChief Medical OfficerSale2,395$2.78$6.7KForm 4
Feb 28, 2022Chevallard Daniel R.CFO and COOSale3,998$2.78$11.1KForm 4
Nov 29, 2021Rojkjaer LisaChief Medical OfficerSale2,591$4.82$12.5KForm 4

All 26 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Viracta Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARViracta Therapeutics, Inc.1
  • CIK0001061027
  • Employer ID (EIN)94-32958781
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address2533 S Coast Hwy 101, Suite 210, Cardiff, CA 920071
  • Phone858-400-84701
  • Shares outstanding39,744,222 as of Nov 11, 202410
  • Public float$50.2M as of Jun 30, 202313
  • On EDGAR sinceAug 7, 20021
  • Filings1,181 in all: 4 (391), 8-K (250), SC 13G/A (81), 3 (64), 10-Q (58), SC 13G (52), 424B5 (37), S-8 (21)1
    All 48 form types

    10-K (19), CORRESP (19), SC 13D/A (19), DEF 14A (18), DEFA14A (13), UPLOAD (13), 424B3 (12), ARS (10), CT ORDER (10), EFFECT (10), 4/A (8), S-3 (8), 425 (7), S-1/A (7), PRE 14A (6), SC 13D (6), 144 (5), REGDEX (4), 3/A (3), S-3/A (3), 10-K/A (2), 8-K/A (2), D (2), REGDEX/A (2), S-1 (2), SC TO-C (2), SC TO-I/A (2), 10-Q/A (1), 25-NSE (1), 424B1 (1), 424B2 (1), 5 (1), 8-A12G (1), NT 10-K (1), POS AM (1), S-3MEF (1), S-4 (1), S-4/A (1), SC TO-I (1), SCHEDULE 13G (1)

  • Latest filingsAnnual report (10-K) Mar 7, 2024
    Quarterly report (10-Q) Nov 13, 2024
    Proxy statement (DEF 14A) Apr 26, 2024
    Latest 8-K (8-K) Feb 5, 2025

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80
  81. 81
  82. 82
  83. 83
  84. 84
  85. 85
  86. 86
  87. 87
  88. 88
  89. 89